What we're about
Upcoming events (1)
PLEASE REGISTER USING THIS LINK: https://www.eventbrite.com/e/vaccine-technology-covid-unwrapped-iot-and-consumer-applications-tickets-171573439777
Vaccine technology has made a lot of progress in the 225 years since Edward Jenner and Kathrine the Second took the inoculation practice of Turkish military doctors to public use. Lots of innovations were adopted after that time, however, the core algorithm still remains the same. The established vaccine technology just mimics the natural process:
1. The adaptive human immune system is presented with and "sees" the most prominent external part of the invading virus - so called “epitopes". These are the viral surface proteins like the corona S-spikes on the surface of coronavirus.
2. That prompts the uniquely specific immune response (antibodies, etc). The protein against which the immune system issues its response is called an ANTIGEN. Today practically all antigens are viral epitopes. And there lies the problem.
This process is very specific to the viral epitope, and thus, the resulting immune response is uniquely specific to the given variant of the virus.
This nature-mimicking approach worked well for a long time for genetically stable DNA viruses, but has serious problems with fast-mutating RNA viruses, whose epitopes quickly mutate and render the immune response less and less effective, as proven by the current pandemic.
Since we cannot do anything to make RNA viruses less mutative, we need to abandon our nature-mimicking epitope-centered vaccine paradigm and enter the new approach in vaccine design - ANTIGEN ENGINEERING for higher vaccine universality (at least across a specific viral family).
Here we will present you the results of almost 25 years of such efforts by two different companies. We present two different, but both highly universal vaccines, both proved in-vivo and protection trials - one already in FDA trials against many adenocarcinomas, and the second, potentially opens a whole new class of viral family-specific vaccines. The last one addresses a very resistant viral family - Herpesviridae, that include many herpes viruses - from genital herpes, to Epstein-Barr, Cytomegalovirus, Kaposi’s sarcoma and more.
Mr. Alex Chaihorsky, M.S. BiographyAlexander Chaihorsky is founder and President of Bio-Virus Research, a bioinformation mathematician, geochemist, software engineer, and military contractor. He has several US patents in the fields of virology, immunology and genetics. Alex has over 40 years' experience in gold and oil exploration, biotech and tech industries, ranging from full cycle development and patenting of synthetic universal peptide vaccine candidates to instant thermoplastic holographic imaging cameras (clients include NASA and West Point Military Academy). He was posted for 2.5 years as Senior Advisor to former Deputy Undersecretary of Defense Paul Brinkley in Afghanistan.
Dr. Babich is co-founder and COO of LabyRx Immunological Therapeutics, where he designed and led a cancer vaccine to FDA approval for clinical trials at the University of California, Davis. He has over 35 years of experience to include faculty positions at the University of Illinois and UC Davis, and as co-founder of multiple start-up biotech companies. Prior to biotechnology, he served in the U.S. Army Medical Service Corps (Colonel) and directed a hospital with international operations. Dr. Babich has over 100 combined papers and patents, and is the recipient of numerous education awards and research grants. He completed his postdoctoral training in the Endocrine Unit at the University of California, San Francisco, and earned his Ph.D. in Pharmacology from the University of Kentucky.